Published in:
01-03-2020 | Paracetamol | Original Article
Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study
Authors:
Nobukazu Okimoto, Akinori Sakai, Toru Yoshioka, Tomohiro Kobayashi, Kei Asano, Shojiro Akahoshi, Toru Ishikura, Shito Fukuhara, Yoshifumi Fuse, Toshiyuki Mizuno, Yuji Katae, Hidehiro Matsumoto, Takayuki Ogawa, Shigeki Nishida, Satoshi Ikeda, Kunitaka Menuki, Jun Saito, Yuichi Okazaki, Naoyuki Mizuno, Saeko Fujiwara
Published in:
Journal of Bone and Mineral Metabolism
|
Issue 2/2020
Login to get access
Abstract
Introduction
Zoledronic acid infusion is used to treat osteoporosis but patients, especially Japanese patients, often experience acute-phase reactions (APRs). In this multicenter, randomized, open-label, parallel-group study, we examined the efficacy of the most commonly used non-steroidal anti-inflammatory drug loxoprofen in Japan in reducing the incidence rate of zoledronic acid-induced APRs and body temperature, and investigated risk/protective factors for APRs in this population.
Materials and methods
Patients aged ≥ 60 years with primary osteoporosis (n = 368) were allocated randomly to zoledronic acid plus loxoprofen (ZOL + LOX) or zoledronic acid alone (ZOL). All patients received 5-mg zoledronic acid infusion on day 1, and patients in the ZOL + LOX group also received 120 mg and 180 mg of oral loxoprofen on days 1 and 2, respectively. Adverse events and body temperature were recorded during the 7-day observation period.
Results
The incidence rates of APRs were 34.4% (64/186 patients) and 47.8% (87/182 patients) in the ZOL + LOX and ZOL groups, respectively (P = 0.0109). The proportions of patients with increased body temperature (≥ 1 °C and ≥ 37.5 °C) were similar in both groups (P = 0.1186). Past bisphosphonate users had a significantly lower incidence rate of APRs than treatment-naïve patients (odds ratio 0.444, 95% confidence interval 0.285–0.692, P = 0.0003).
Conclusions
Zoledronic acid-induced APRs appeared to be suppressed by loxoprofen. Known risk/protective factors, including prior osteoporosis treatment, were applicable to Japanese patients.